{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:57:08Z","timestamp":1770814628808,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00535-023-02041-3","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T14:04:01Z","timestamp":1695132241000},"page":"1188-1197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9327-6767","authenticated-orcid":false,"given":"Kosuke","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Shimozuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"2041_CR1","unstructured":"Cancer Statistics\u201922. National Cancer Center. https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/pdf\/cancer_statistics_2022.pdf. Accessed 28 Nov 2022"},{"key":"2041_CR2","unstructured":"Cancer Information Service, National Cancer Center, Japan. Annual survival report of hospital-based cancer registries. https:\/\/hbcr-survival.ganjoho.jp\/. Accessed 28 Nov 2022"},{"key":"2041_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.18457","volume":"4","author":"MCS Wong","year":"2021","unstructured":"Wong MCS, Huang J, Chan PSF, et al. Global incidence and mortality of gastric cancer, 1980\u20132018. JAMA Netw Open. 2021;4: e2118457.","journal-title":"JAMA Netw Open"},{"key":"2041_CR4","volume-title":"Gastric cancer treatment guidelines","author":"Japanese Gastric Cancer Association","year":"2021","unstructured":"Japanese Gastric Cancer Association. Gastric cancer treatment guidelines. Japan: Kinbara Publishing Co., Ltd; 2021."},{"key":"2041_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"2041_CR6","unstructured":"Trends in medical expenses. Ministry of Health, Labour and Welfare. https:\/\/www.mhlw.go.jp\/topics\/medias\/year\/21\/index.html. Accessed 28 Nov 2022"},{"key":"2041_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11096-021-01372-6","volume":"44","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Li Y, Wang LXW. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Int J Clin Pharm. 2022;44:499\u2013506.","journal-title":"Int J Clin Pharm"},{"key":"2041_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1248\/bpb.b22-00150","volume":"45","author":"M Kashiwa","year":"2022","unstructured":"Kashiwa M, Matsushita R. Difference in cost-effectiveness between first-line and third-line or later nivolumab therapy in patients with HER2-negative, unresectable, advanced or recurrent gastric or gastro-esophageal junction cancer in Japan. Biol Pharm Bull. 2022;45:895\u2013903.","journal-title":"Biol Pharm Bull"},{"key":"2041_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","volume":"23","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa M, Komoto S, Shiroiwa T, et al. Formal implementation of cost-effectiveness evaluations in japan: a unique health technology assessment System. Value Health. 2020;23:43\u201351.","journal-title":"Value Health"},{"key":"2041_CR10","unstructured":"NICE Decision Support Unit. NICE DSU TECHNICAL SUPPORT DOCUMENT 19: partitioned survival analysis for decision modelling in health care: a critical review. https:\/\/www.sheffield.ac.uk\/sites\/default\/files\/2022-02\/TSD19-Partitioned-Survival-Analysis-final-report.pdf. Accessed 29 Nov 2022"},{"key":"2041_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40273-013-0123-9","volume":"32","author":"V Diaby","year":"2014","unstructured":"Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics. 2014;32:101\u20138.","journal-title":"Pharmacoeconomics"},{"key":"2041_CR12","unstructured":"CORE2 Health. Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council Version 3.0 approved by CSIMC on 19th January, 2022. https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf. Accessed 29 Sept 2020"},{"key":"2041_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"2041_CR14","unstructured":"Ministry of Health, Labour, and Welfare. Guidelines for Promoting the Proper Use of Nivolumab in Gastric Cancer. https:\/\/www.mhlw.go.jp\/content\/12404000\/000860764.pdf. Accessed 29 Nov 2022"},{"key":"2041_CR15","unstructured":"Portal Site of Official Statistics of Japan (e-Stat). https:\/\/www.e-stat.go.jp\/dbview?sid=0003224177. Accessed 29 Nov 2022"},{"key":"2041_CR16","unstructured":"KEGG: Kyoto Encyclopedia of Genes and Genomes. https:\/\/www.kegg.jp\/medicus-bin\/japic_med?japic_code=00069048. Accessed 29 Nov 2022"},{"key":"2041_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"2041_CR18","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1634\/theoncologist.2014-0058","volume":"19","author":"T Satoh","year":"2014","unstructured":"Satoh T, Bang YJ, Gotovkin EA, et al. Quality of life in the trastuzumab for gastric cancer trial. Oncologist. 2014;19:712\u20139.","journal-title":"Oncologist"},{"key":"2041_CR19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/bjc.2011.390","volume":"105","author":"T Shiroiwa","year":"2011","unstructured":"Shiroiwa T, Fukuda T, Shimozuma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer. 2011;105:1273\u20138.","journal-title":"Br J Cancer"},{"key":"2041_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Y-K Kang","year":"2022","unstructured":"Kang Y-K, Chen L-T, Ryu M-H, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234\u201347.","journal-title":"Lancet Oncol"},{"key":"2041_CR21","unstructured":"Food and Drug Administration (FDA). https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-combination-chemotherapy-metastatic-gastric-cancer-and-esophageal. Accessed 29 Nov 2022"},{"key":"2041_CR22","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.healthpol.2017.06.001","volume":"121","author":"T Shiroiwa","year":"2017","unstructured":"Shiroiwa T, Fukuda T, Ikeda S, et al. New decision-making processes for the pricing of health technologies in Japan: the FY 2016\/2017 pilot phase for the introduction of economic evaluations. Health Policy. 2017;121:836\u201341.","journal-title":"Health Policy"},{"key":"2041_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1017\/S0266462320000264","volume":"36","author":"T Shiroiwa","year":"2020","unstructured":"Shiroiwa T. Cost-effectiveness evaluation for pricing medicines and devices: a new value-based price adjustment system in Japan. Int J Technol Assess Health Care. 2020;36:270\u20136.","journal-title":"Int J Technol Assess Health Care"},{"key":"2041_CR24","unstructured":"Medical Economics Division, Health Insurance Bureau, Ministry of Health Labour and Welfare (MHLW). Full scale introduction of cost-effectiveness evaluations in Japan. 2019 https:\/\/c2h.niph.go.jp\/tools\/system\/overview_en.pdf. Accessed 29 Nov 2022"},{"key":"2041_CR25","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Nivolumab review report. https:\/\/www.pmda.go.jp\/drugs\/2021\/P20211208001\/180188000_22600AMX00768_A100_1.pdf. Accessed 29 Nov 2022"},{"key":"2041_CR26","unstructured":"National Institute for Health and Care Excellence (NICE). Appraisal consultation document. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10352\/documents. Accessed 29 Nov 2022"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-02041-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-023-02041-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-02041-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T15:03:22Z","timestamp":1700406202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-023-02041-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2041"],"URL":"https:\/\/doi.org\/10.1007\/s00535-023-02041-3","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"14 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takeo Nakayama received Per diem, honorariums, etc. from Pfizer Japan, Janssen Pharmaceutical K. K., Boehringer Ingelheim, Eli Lilly Japan K. K., Mitsubishi Tanabe Pharma, Dentsu, and Otsuka Pharmaceutica. He also received Research grants from I&H co., Ltd., Cocokarafine Co., Ltd., and Konica Minolta Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}